Ti-6Al-7Nb in Medical Applications: Clinical Evidence and Uses

The development of medical titanium and titanium alloys can be broadly divided into three stages.

Ti-6Al-4V. Commercially pure titanium offers excellent biocompatibility and has been used in dental and surgical implants since the 1960s. However, its relatively low strength and limited wear resistance have restricted its use in some load-bearing applications. As an alpha-beta titanium alloy, Ti-6Al-4V offers higher strength and good processability. Since the 1970s, it has been used in bone plates, intramedullary nails, joint replacements, and other medical implants. However, concerns have been raised about the potential biological effects of aluminium and vanadium. Studies have investigated the effects of vanadium compounds on enzyme activity, while excessive aluminium exposure has been associated with adverse effects on bone health, blood function, and the nervous system.

Ti-6Al-7Nb and Ti-5Al-2.5Fe, which use niobium or iron instead of vanadium. These alloys offer mechanical properties and elastic moduli broadly comparable to those of established titanium materials, while providing alternative alloying systems. In 1985, the Swiss company Sulzer introduced a hip prosthesis femoral stem made from Ti-6Al-7Nb for clinical use. Ti-5Al-2.5Fe, meanwhile, saw more limited adoption because of challenges related to metallurgical quality and processing.

The third stage focuses on newer beta titanium alloys that contain neither aluminium nor vanadium, such as Ti-13Nb-13Zr, Ti-12Mo-6Zr-2Fe, and Ti-15Mo. These alloys are being investigated for their combination of high strength, good biocompatibility, and lower elastic moduli that may more closely match that of human bone.

Ti-6Al-7Nb occupies an important position in this development. It offers mechanical properties comparable to those of Ti-6Al-4V while replacing vanadium with niobium. But where is Ti-6Al-7Nb actually used in the medical field, and what does the clinical evidence tell us about its performance?

IU Jian-qiao, LIU Jia, TANG Yu-jin, WANG Li-qiang. Research progress in titanium alloy in the field of orthopaedic implants. , 2021, 49(8): 11–25.

A material's acceptance in the medical industry depends on more than its laboratory properties. It also depends on whether it can meet engineering requirements and perform reliably in clinical use. The following sections examine the applications of Ti-6Al-7Nb in joint replacement, dental implants, and spinal and craniofacial surgery, along with the available clinical and experimental evidence.

Joint replacement is one of the earliest and most extensively studied clinical applications of Ti-6Al-7Nb. In 1985, Sulzer in Switzerland used this alloy to manufacture a hip prosthesis femoral stem. Since then, various stem designs have been introduced into clinical practice.

The following three independent studies cover different clinical settings: primary cementless hip replacement, revision surgery, and cemented fixation.

Vektor-Titan cementless stem: 250 hip replacements

In a study of 250 hip replacements, the mean follow-up period was 3.0 years. The Merle d'Aubigné score improved from 9.3 before surgery to 17.0 after surgery. Stable proximal fixation was achieved in 242 of the 250 cases (96.8%).

Modular Ti-6Al-7Nb revision stem: 130 cases

This study examined 130 cementless revision procedures, with a mean follow-up period of 2.9 years. The Harris Hip Score improved from 50.9 to 88.5, and stable initial fixation was achieved in 129 of the 130 cases.

Müller cemented straight stem: nine-year follow-up

A prospective study of 126 cases reported an overall survival rate of 96.8% at nine years and a survival rate of 98.4% without aseptic loosening.

One important finding is that earlier studies had reported high loosening rates for some cemented titanium alloy stems. The Müller study highlights the importance of evaluating implant design, surface condition, cementing technique, and surgical practice together rather than attributing clinical outcomes to the material alone.

Taken together, these studies provide clinical evidence for the use of Ti-6Al-7Nb in different hip replacement settings. However, their results relate to specific implant designs, patient populations, and follow-up periods. They should not be interpreted as proof that every Ti-6Al-7Nb implant will achieve the same outcomes.

Dental implants are exposed to a complex environment involving saliva, microorganisms, and repeated chewing loads. These conditions place considerable demands on both fatigue resistance and biocompatibility.

A cyclic fatigue study conducted in accordance with ISO 14801 reported a cyclic yield force of 853 ± 202 N for Ti-6Al-7Nb. This was comparable to the value reported for Ti-6Al-4V (870 ± 58 N) and higher than the value reported for Grade 4 commercially pure titanium, which was below 700 N.

For applications involving narrow alveolar ridges, where implants with smaller diameters may be required, fatigue performance is an important factor in material selection. The study suggests that Ti-6Al-7Nb may provide a greater fatigue-strength margin than Grade 4 titanium under the tested conditions.

Biocompatibility is an important consideration when selecting materials for dental implants. For patients with a history of metal hypersensitivity, potentially allergenic elements such as nickel deserve particular attention.

Some studies have reported that nickel impurities may be present in certain titanium materials as a result of the manufacturing process. This highlights the importance of raw material purity and process control when manufacturing medical implant materials.

Ti-6Al-7Nb provides another titanium alloy option for dental and other medical implant applications. However, its alloy composition alone does not establish that it is safer for patients with nickel allergies. Biocompatibility also depends on impurity levels, surface condition, manufacturing processes, and the intended application. Material selection should therefore be supported by appropriate test results and relevant clinical evidence.

Ti-6Al-7Nb does not inherently possess the same bioactive characteristics as certain bioactive coating materials. Surface modification may therefore be used to promote bone integration.

A 2025 study investigated a magnesium-doped hydroxyapatite coating deposited on Ti-6Al-7Nb. In vitro testing showed no cytotoxicity or inflammatory response associated with the coated material, while the uncoated Ti-6Al-7Nb samples triggered inflammatory signalling under the tested conditions.

These findings suggest that surface modification may influence the biological response to Ti-6Al-7Nb. However, in vitro results alone cannot establish clinical performance, and further evidence may be needed to determine how these findings translate into actual implant use.

Read the 2025 study on ScienceDirect

Ti-6Al-7Nb has also been used in certain spinal and craniofacial implant products.

For example, the T-PAL interbody fusion cage made from Ti-6Al-7Nb alloy conforming to ISO 5832-11 is used in selected spinal procedures. Potential clinical settings include certain degenerative lumbar conditions, spinal instability, and revision surgery, subject to the product's approved indications.

Some craniofacial fixation systems also use Ti-6Al-7Nb for bone fixation screws.

The use of this alloy in these applications reflects the need to balance mechanical strength, corrosion resistance, biocompatibility, and implant design. The suitability of a particular product depends on its design, intended use, applicable standards, and clinical evidence.

The elastic modulus of Ti-6Al-7Nb is approximately 105 GPa, compared with approximately 110 GPa for Ti-6Al-4V. Actual values may vary depending on the material condition and test method.

Although the difference is relatively small, elastic modulus can be relevant when evaluating load transfer between an implant and surrounding bone. A mismatch in stiffness may contribute to stress shielding, in which the implant carries a disproportionate share of the load and reduces the mechanical stimulus experienced by the surrounding bone.

A lower elastic modulus may help improve load distribution under certain conditions. However, clinical performance also depends on implant geometry, porosity, implant position, bone quality, and other factors. Elastic modulus alone is not sufficient to predict the outcome of a spinal fusion procedure or other implant application.

For this reason, Ti-6Al-7Nb should be evaluated as part of the complete implant system rather than selected solely because of its nominal elastic modulus.

Ti-6Al-7Nb has established applications in joint replacement, dental implants, and certain spinal and craniofacial devices. Clinical studies of hip replacement provide evidence of its use in both primary and revision procedures, while dental research has examined its fatigue performance, biocompatibility, and potential for surface modification.

Its value does not lie simply in being stronger than other titanium materials. Rather, Ti-6Al-7Nb offers a combination of mechanical properties and an alloying system that replaces vanadium with niobium. This makes it an option worth evaluating when selecting materials for medical implants.

For manufacturers, engineers, and medical device purchasers, the choice should be based on the intended application, mechanical requirements, material certification, biological evaluation, and relevant clinical evidence. If your project has specific requirements concerning alloy composition or biological safety, Ti-6Al-7Nb may be worth including in your material assessment.

titanium bar and rod category.